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Angiotensin II and endothelin in chronic glomerulonephritis
Glomerulopathies that result in substantial renal damage
frequently are characterized by relentless progression to
end-stage renal disease. This process typically involves
glomerular sclerosis and interstitial fibrosis and occurs
regardless of the nature of the initial renal insult. The
mechanisms responsible for continued renal deterioration
are not fully understood, but may be distinct from those
responsible for the original injury. Glomerular hyperten-
sion, glomerular cell hypertrophy, and extracellular matrix
accumulation all appear to be involved. Numerous studies
support a role for angiotensin II (Ang II). Renal Ang II
production is enhanced in chronic glomerulopathies, while
the peptide can elevate intraglomerular pressure, increase
glomerular cell hypertrophy, and augment extracellular
matrix accumulation [1]. Ang II antagonists or synthesis
inhibitors markedly slow, and can even prevent, renal
deterioration in experimental models of progressive renal
failure [1–3]. Studies in humans on the efficacy of angio-
tensin converting enzyme inhibitors (ACEI) in non-diabetic
chronic renal failure have suggested, but not conclusively
demonstrated, a beneficial effect on preservation of renal
function [4]. This may reflect the relatively short-term
nature and small sample size of these studies, but may also
be an indication that factors other than Ang II play an
important role in progression of renal failure.
One such factor that has been implicated in the nephro-
sclerotic process is endothelin (ET). ET is a potent vaso-
constrictor, stimulates glomerular cell proliferation and
hypertrophy, and enhances extracellular matrix accumula-
tion [5]. Renal production of this 21-amino acid peptide is
increased in virtually all forms of chronic renal disease.
Since ET was only identified a decade ago, there have been
no reports on the efficacy of ET antagonism in humans with
renal disease; however, blockade of ET receptors amelio-
rates glomerular injury in a wide variety of experimental
models of chronic renal failure [5]. In addition, mice
transgenic for endothelin-1 develop substantial glomerulo-
sclerosis and interstitial fibrosis, which occurs despite no
detectable change in blood pressure [6]. Thus, there is
ample reason to suspect that ET is involved in progressive
renal failure.
The above considerations raise the question as to
whether the combined blockade of ET and Ang II action
would better preserve renal function in chronic glomeru-
lopathies than is afforded by inhibition of either factor
alone. This important issue has not previously been studied.
Indeed, the only relevant data are from studies using a
model of chronic cyclosporine nephrotoxicity in which the
effect of ET receptor blockers and ACEI were compared
[7]. ET receptor inhibition markedly preserved renal func-
tion, but did not affect arteriolopathy or interstitial fibrosis.
In contrast, ACEI reduced structural injury, but failed to
protect the glomerular filtration rate. Thus, these studies
suggest that there may indeed be merit to combined
inhibition of ET and Ang II action in the treatment of
progressive renal failure. It is in this setting that the studies
reported in this issue of Kidney International are so timely
[8]. Benigni et al examined the effect of trandolapril (an
ACEI), endothelin A (ETA) receptor blockade, or com-
bined therapy, on renal structure and function in rats
uninephrectomized one week after a single injection of
rabbit anti-Fx1A antibody (accelerated passive Heyman
nephritis PHN). After eight months of continuous treat-
ment, neither agent alone significantly affected serum
creatinine or proteinuria, while combination therapy mark-
edly protected against functional deterioration and reduced
the degree of proteinuria. Similarly, single drug adminis-
tration did not alter tubulointerstitial damage or the num-
ber of glomeruli with sclerotic changes, while both agents
together significantly ameliorated glomerular and tubulo-
interstitial structural injury. Thus, the combined inhibition
of Ang II and ET-1 action may be better than inhibition of
either agent alone in preserving renal structure and func-
tion in chronic proteinuric renal failure.
Should we now be treating chronic glomerulopathies
with inhibitors of Ang II and ET action? Several consider-
ations with regards to the Benigni et al study must be
undertaken before arriving at this conclusion. First, blood
pressure tended (although it was not statistically signifi-
cant) to be lower in animals treated with combination
therapy than with single agents alone. In addition, unlike
other experimental glomerulopathy models, ACEI alone
had no effect on GFR or proteinuria. The authors ascribe
this lack of an ACEI effect to the relatively greater disease
severity in the current study; if true, these studies could
provide a rationale for combined drug therapy even in
more severe stages of chronic renal failure. Lastly, an ETA
receptor inhibitor was used, leaving endothelin B (ETB)
receptors available for increased ET-1 binding. The signif-
icance of this is unknown, since the role of ETA and ETB
receptors in mediating renal dysfunction and sclerosis in
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humans remains speculative. Nonetheless, since ETB, but
not ETA, receptor mRNA may be elevated following renal
injury [9], and since ETB receptors can mediate renal
vasoconstriction in the rat [5], the possibility is raised that
antagonizing both ETA and ETB receptors may provide
even greater benefit. Clearly, further studies are needed on
the efficacy of combined therapy with ET and Ang II
inhibitors in experimental glomerulopathies. If, as the
studies by Benigni et al suggest, combined blockade proves
beneficial, we need to rapidly examine the effects of many
of the newly developed ET receptor antagonists, both alone
and in combination with ACEI or Ang II receptor blockers,
in chronic renal failure.
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